Related Experiment Video
Updated: Nov 28, 2025

Olfactory Assays for Mouse Models of Neurodegenerative Disease
Published on: August 25, 2014
Olfactory Dysfunction in Patients With Relapsing-Remitting Multiple Sclerosis Treated With Disease-Modifying
Marcin Wnuk1,2, Leszek Drabik3,4, Monika Marona1,2
1Department of Neurology, Jagiellonian University Medical College, Krakow, Poland.
Background:
Olfactory dysfunction evaluated with time-consuming tests was more common in patients with multiple sclerosis (MS) than in controls and correlated with neurological deficit. The aim of the present study was to compare olfactory function between patients with relapsing-remitting MS (RRMS) and controls with short and simple screening tool-the Sniffin' Sticks Identification Test (SSIT)-and search for its association with clinical and radiological features of the disease.
Methods:
The study included 30 controls and 30 patients with RRMS treated with disease-modifying therapies-injectables (interferon β or glatiramer acetate, N = 18) and oral drugs (dimethyl fumarate or fingolimod, N = 12). Hyposmia was defined as a score of 6 points or fewer in the SSIT olfactory test. The data concerning number of previous relapses, disability in Expanded Disability Status Scale (EDSS), and recent brain magnetic resonance imaging (MRI) scan were collected. Moreover, thalamic volume and third ventricle width were recorded in every patient. Additionally, cognition and fatigue in patients were evaluated 24 months after olfactory assessment with the Symbol Digit Modalities Test (SDMT) and Fatigue Scale for Motor and Cognitive Functions (FSMC), respectively.
Results:
Patients with RRMS had a higher risk of hyposmia than controls (66.7% vs 36.7%, OR = 1.82, 95% CI, 1.10-3.67, P = .02). Neither inflammatory (number of previous relapses or new brain MRI lesions) nor neurodegenerative (EDSS, SDMT, and FSMC scores; thalamic volume; third ventricle width) MS features did not correlate with SSIT score (P > .05). In patients treated with oral drugs, olfactory dysfunction correlated with FSMC cognitive subscale (r = -0.90, P = .006).
Conclusions:
Olfactory dysfunction is nearly twice as common in RRMS as in controls and correlates with fatigue level in patients treated with dimethyl fumarate or fingolimod.
Insights
Olfactory dysfunction is nearly twice as common in relapsing-remitting multiple sclerosis (RRMS) patients compared to controls. This dysfunction was found to correlate with fatigue in patients taking oral disease-modifying therapies.
Area of Science:
- Neurology
- Neuroscience
- Olfactory Research
Background:
- Olfactory dysfunction is more prevalent in multiple sclerosis (MS) patients than controls.
- Previous olfactory assessments were time-consuming.
- Correlation between olfactory deficit and neurological impairment in MS was previously noted.
Purpose of the Study:
- To compare olfactory function in relapsing-remitting MS (RRMS) patients versus controls using a rapid screening tool.
- To investigate the association between olfactory function and clinical/radiological features in RRMS.
Main Methods:
- Utilized the Sniffin' Sticks Identification Test (SSIT) for olfactory screening in 30 RRMS patients and 30 controls.
- Collected data on relapses, Expanded Disability Status Scale (EDSS), brain MRI, thalamic volume, and third ventricle width.
- Assessed cognition (Symbol Digit Modalities Test - SDMT) and fatigue (Fatigue Scale for Motor and Cognitive Functions - FSMC) 24 months post-olfactory testing.
Main Results:
- RRMS patients exhibited a significantly higher risk of hyposmia (66.7%) compared to controls (36.7%).
- No significant correlation was found between olfactory scores and inflammatory or neurodegenerative MS markers.
- Olfactory dysfunction correlated with fatigue (FSMC cognitive subscale) in RRMS patients on oral medications.
Conclusions:
- Olfactory dysfunction is nearly twice as common in RRMS patients compared to healthy controls.
- Olfactory dysfunction is linked to fatigue in RRMS patients treated with oral therapies like dimethyl fumarate or fingolimod.
Related Concept Videos
Olfactory Receptors: Location and Structure
Olfaction
The olfactory receptors are embedded in the cilia of the...
Physiology of Smell and Olfactory Pathway
The olfactory...
Taste Buds and Receptors
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...

